This activity is supported by an independent education grant from Genmab. This online education program has been designed solely for healthcare professionals in the USA. The information in this program is not suitable for any other country.

Join leading expert Dr. Paolo Strati for this accredited virtual workshop. This highly interactive toxicity management workshop focuses on the prompt recognition, grading, escalation, and multidisciplinary management of adverse events associated with bispecific antibody therapy. Utilizing real-time polling and simulated patient cases, participants will learn to differentiate cytokine release syndrome (CRS) from infusion-related reactions or infection, apply the ICE scoring system for immune effector cell-associated neurotoxicity syndrome (ICANS), manage severe cytopenias and infectious complications, and implement consensus-based intervention algorithms across outpatient and acute care settings.

This workshop is part of a series. Register for workshop 1, 2 and 4 below:

Workshop 1 - Selecting the Right Patient at the Right Time

Workshop 2 - From Prescription to First Dose

Workshop 4 - Building a Bispecific-Ready Practice

Session Highlights

• Apply consensus grading systems (ASTCT) to accurately recognize and grade CRS, ICANS, and overlapping toxicities in patients receiving bispecific antibodies.
• Execute evidence-based management algorithms, including the appropriate timing and administration of dexamethasone, tocilizumab, and supportive care measures.
• Utilize diagnostic evaluation tools (e.g., ICE score assessment, infection workups) to distinguish immune-mediated adverse events from alternative etiologies.
• Implement prophylactic protocols to reduce the risk of infectious complications, neutropenia, and severe adverse events during step-up dosing.
• Engage in interactive decision-making scenarios to establish timely escalation triggers and multidisciplinary communication pathways during urgent toxicity events.

Who Should Attend

This program is designed for:

• Community oncologists
• Community hematologists and hematology-oncologists
• Advanced practice providers (APPs)
• Nurse practitioners
• Oncology nurses
• Pharmacists
• Multidisciplinary care team members involved in treatment delivery and monitoring

Faculty

Paolo Strati, MD – Associate Professor, with Term Tenure, Deputy Section Chief for Indolent B-cell Lymphomas, Fellowship Director and CARTOX Program Leader in the Department of Lymphoma and Myeloma with a joint appointment in the Department of Translational Molecular Pathology, at the University of Texas MD Anderson Cancer Center, in Houston, Texas. Dr. Strati is a recognized expert in the field of immunotherapy and cellular therapy for the treatment of B-cell lymphoma, and he is the principal investigator of multiple clinical trials and translational projects related to this topic.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

Paolo Strati, MD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory Board for Abbvie-Genmab, ADC Therapeutics, Astrazeneca Acerta, BeOne, Incyte, Kite-Gilead, Lilly, Merck, Novartis, Regeneron, Roche-Genentech, and Sobi; Consultant for Abbvie-Genmab, ADC Therapeutics, Astrazeneca Acerta, BeOne, Incyte, Kite-Gilead, Lilly, Merck, Novartis, Regeneron, Roche-Genentech, and Sobi; Grant/Research Support from ADC Therapeutics, ALX Oncology, Astrazeneca Acerta, Kite-Gilead, Leukemia Lymphoma Society (now Blood Cancer United), and Sobi.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until November 12, 2026. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-346-L01-P

Type of Activity: Application

Fee information

There is no fee for this educational activity.